

USA, API (1998-2012)

	Number of cases							Percentage				Incidence rates per million person-years							MV % 0-19	DCO % 0-19		
	Age group							0-14		0-19		Age-specific					Cumulative					
	0	1-4	5-9	10-14	15-19	0-14	0-19	All	Group	All	Group	0	1-4	5-9	10-14	15-19	0-14	0-19			0-14	0-19
I LEUKAEMIA	134	887	520	375	369	1916	2285	35.5	100.0	29.7	100.0	42.8	71.7	34.9	25.5	24.0	44.1	39.6	631	751	97.6	0.6
a. Lymphoid	59	719	411	229	170	1418	1588	26.3	74.0	20.6	69.5	18.8	58.1	27.6	15.5	11.1	32.8	27.9	466	522	98.9	0.3
b. Acute myeloid	50	126	75	98	121	349	470	6.5	18.2	6.1	20.6	16.0	10.2	5.0	6.7	7.9	7.9	7.9	115	155	98.9	0.4
c. CMD	8	7	13	31	48	59	107	1.1	3.1	1.4	4.7	2.6	0.6	0.9	2.1	3.1	1.3	1.7	20	35	84.1	5.6
d. MDS & other	13	22	11	6	14	52	66	1.0	2.7	0.9	2.9	4.1	1.8	0.7	0.4	0.9	1.2	1.2	17	22	87.9	0.0
e. Unspecified	4	13	10	11	16	38	54	0.7	2.0	0.7	2.4	1.3	1.1	0.7	0.7	1.0	0.9	0.9	13	18	88.9	3.7
II LYMPHOMA & RELATED	34	131	178	249	448	592	1040	11.0	100.0	13.5	100.0	10.9	10.6	11.9	16.9	29.1	12.9	16.5	197	343	98.5	0.4
a. Hodgkin	0	15	38	93	229	146	375	2.7	24.7	4.9	36.1	-	1.2	2.5	6.3	14.9	3.0	5.7	49	124	99.5	0.0
b. Non-Hodgkin except BL	7	49	87	118	176	261	437	4.8	44.1	5.7	42.0	2.2	4.0	5.8	8.0	11.4	5.6	6.9	87	144	99.3	0.0
c. Burkitt (BL)	0	23	39	26	28	88	116	1.6	14.9	1.5	11.2	-	1.9	2.6	1.8	1.8	1.9	1.9	29	38	98.3	0.9
d. Lymphoreticular	27	42	13	9	8	91	99	1.7	15.4	1.3	9.5	8.6	3.4	0.9	0.6	0.5	2.2	1.8	30	32	97.0	2.0
e. Unspecified	0	2	1	3	7	6	13	0.1	1.0	0.2	1.3	-	0.2	0.1	0.2	0.5	0.1	0.2	2	4	53.8	7.7
III CNS NEOPLASMS †	92	346	355	274	327	1067	1394	19.8	100.0	18.1	100.0	29.4	28.0	23.8	18.6	21.3	24.0	23.4	353	460	79.4	0.8
a. Ependymoma	19	47	28	15	31	109	140	2.0	10.2	1.8	10.0	6.1	3.8	1.9	1.0	2.0	2.5	2.4	36	46	98.6	0.0
b. Astrocytoma	27	132	116	116	107	391	498	7.2	36.6	6.5	35.7	8.6	10.7	7.8	7.9	7.0	8.8	8.4	130	164	89.4	0.2
c. CNS embryonal	29	83	97	39	29	248	277	4.6	23.2	3.6	19.9	9.3	6.7	6.5	2.6	1.9	5.7	4.8	82	91	98.6	0.4
d. Other gliomas	3	43	82	43	34	171	205	3.2	16.0	2.7	14.7	1.0	3.5	5.5	2.9	2.2	3.8	3.4	57	68	36.6	1.5
e. Other specified	5	30	31	52	118	118	236	2.2	11.1	3.1	16.9	1.6	2.4	2.1	3.5	7.7	2.6	3.7	39	78	69.5	0.0
f. Unspecified CNS	9	11	1	9	8	30	38	0.6	2.8	0.5	2.7	2.9	0.9	0.1	0.6	0.5	0.7	0.7	10	12	31.6	15.8
IV NEUROBLASTOMA	101	178	36	4	12	319	331	5.9	100.0	4.3	100.0	32.2	14.4	2.4	0.3	0.8	7.8	6.2	103	107	97.3	0.0
a. (Ganglio)neuroblastoma	101	178	36	4	5	319	324	5.9	100.0	4.2	97.9	32.2	14.4	2.4	0.3	0.3	7.8	6.1	103	105	97.2	0.0
b. Peripheral nervous	0	0	0	0	7	0	7	-	-	0.1	2.1	-	-	-	-	0.5	-	0.1	-	2	100.0	0.0
V RETINOBLASTOMA	59	96	5	0	0	160	160	3.0	100.0	2.1	100.0	18.8	7.8	0.3	-	-	4.0	3.1	52	52	76.9	1.3
VI RENAL TUMOURS	27	109	26	9	15	171	186	3.2	100.0	2.4	100.0	8.6	8.8	1.7	0.6	1.0	4.1	3.4	56	61	98.4	1.1
a. Nephroblastoma	27	107	24	6	5	164	169	3.0	95.9	2.2	90.9	8.6	8.6	1.6	0.4	0.3	4.0	3.2	53	55	100.0	0.0
b. Renal carcinoma	0	0	2	3	10	5	15	0.1	2.9	0.2	8.1	-	-	0.1	0.2	0.7	0.1	0.2	2	5	93.3	6.7
c. Unspecified	0	2	0	0	0	2	2	0.0	1.2	0.0	1.1	-	0.2	-	-	-	0.0	0.0	1	1	0.0	50.0
VII HEPATIC TUMOURS	42	79	19	16	30	156	186	2.9	100.0	2.4	100.0	13.4	6.4	1.3	1.1	2.0	3.7	3.3	51	61	96.2	0.0
a. Hepatoblastoma	38	78	9	3	2	128	130	2.4	82.1	1.7	69.9	12.1	6.3	0.6	0.2	0.1	3.1	2.5	41	42	97.7	0.0
b. Hepatic carcinoma	3	0	10	13	28	26	54	0.5	16.7	0.7	29.0	1.0	-	0.7	0.9	1.8	0.5	0.8	9	18	92.6	0.0
c. Unspecified	1	1	0	0	0	2	2	0.0	1.3	0.0	1.1	0.3	0.1	-	-	-	0.0	0.0	1	1	100.0	0.0
VIII BONE TUMOURS	3	15	64	131	168	213	381	3.9	100.0	4.9	100.0	1.0	1.2	4.3	8.9	10.9	4.4	5.9	72	126	99.0	0.3
a. Osteosarcoma	0	3	43	96	104	142	246	2.6	66.7	3.2	64.6	-	0.2	2.9	6.5	6.8	2.9	3.8	48	82	100.0	0.0
b. Chondrosarcoma	0	1	0	2	7	3	10	0.1	1.4	0.1	2.6	-	0.1	-	0.1	0.5	0.1	0.2	1	3	90.0	0.0
c. Ewing & related	3	9	14	26	42	52	94	1.0	24.4	1.2	24.7	1.0	0.7	0.9	1.8	2.7	1.1	1.5	17	31	100.0	0.0
d. Other specified	0	2	7	5	12	14	26	0.3	6.6	0.3	6.8	-	0.2	0.5	0.3	0.8	0.3	0.4	5	9	96.2	0.0
e. Unspecified	0	0	0	2	3	2	5	0.0	0.9	0.1	1.3	-	-	-	0.1	0.2	0.0	0.1	1	2	60.0	20.0
IX SOFT TISSUE SARCOMA	28	76	61	103	162	268	430	5.0	100.0	5.6	100.0	8.9	6.1	4.1	7.0	10.5	5.9	7.0	89	142	99.5	0.2
a. Rhabdomyosarcoma	15	59	32	33	33	139	172	2.6	51.9	2.2	40.0	4.8	4.8	2.1	2.2	2.1	3.2	3.0	46	57	99.4	0.0
b. Fibrosarcoma	7	6	6	12	15	31	46	0.6	11.6	0.6	10.7	2.2	0.5	0.4	0.8	1.0	0.7	0.8	10	15	100.0	0.0
c. Kaposi sarcoma	0	0	0	0	1	0	1	-	-	0.0	0.2	-	-	-	-	0.1	-	0.0	-	0	100.0	0.0
d. Other specified	3	10	16	43	85	72	157	1.3	26.9	2.0	36.5	1.0	0.8	1.1	2.9	5.5	1.5	2.4	24	52	100.0	0.0
e. Unspecified	3	1	7	15	28	26	54	0.5	9.7	0.7	12.6	1.0	0.1	0.5	1.0	1.8	0.5	0.8	9	18	98.1	1.9
X GERM CELL TUMOURS	57	63	54	147	295	321	616	5.9	100.0	8.0	100.0	18.2	5.1	3.6	10.0	19.2	7.1	9.8	107	203	96.1	0.0
a. CNS germ cell ‡	5	10	28	81	62	124	186	2.3	38.6	2.4	30.2	1.6	0.8	1.9	5.5	4.0	2.6	2.9	42	62	91.9	0.0
b. Other extragonadal	33	21	3	8	40	65	105	1.2	20.2	1.4	17.0	10.5	1.7	0.2	0.5	2.6	1.6	1.8	21	34	94.3	0.0
c. Gonadal germ cell	18	32	23	54	162	127	289	2.4	39.6	3.8	46.9	5.7	2.6	1.5	3.7	10.5	2.8	4.5	42	95	99.7	0.0
d. Gonadal carcinoma	0	0	0	3	26	3	29	0.1	0.9	0.4	4.7	-	-	-	0.2	1.7	0.1	0.4	1	9	96.6	0.0
e. Unspecified gonadal	1	0	0	1	5	2	7	0.0	0.6	0.1	1.1	0.3	-	-	0.1	0.3	0.0	0.1	1	2	85.7	0.0
XI CARCINOMA & MELANOMA	6	17	32	142	468	197	665	3.7	100.0	8.6	100.0	1.9	1.4	2.1	9.6	30.4	4.1	10.0	66	218	98.9	0.3
a. Adrenocortical	1	3	1	2	1	7	8	0.1	3.6	0.1	1.2	0.3	0.2	0.1	0.1	0.1	0.2	0.1	2	3	87.5	0.0
b. Thyroid	0	2	9	80	289	91	380	1.7	46.2	4.9	57.1	-	0.2	0.6	5.4	18.8	1.8	5.6	31	125	100.0	0.0
c. Nasopharyngeal	0	0	3	10	30	13	43	0.2	6.6	0.6	6.5	-	-	0.2	0.7	2.0	0.3	0.6	4	14	97.7	0.0
d. Melanoma	2	11	6	11	23	30	53	0.6	15.2	0.7	8.0	0.6	0.9	0.4	0.7	1.5	0.7	0.9	10	17	96.2	0.0
e. Skin carcinoma	1	0	1	0	0	2	2	0.0	1.0	0.0	0.3	0.3	-	0.1	-	-	0.0	0.0	1	1	100.0	0.0
f. Other & unspecified	2	1	12	39	125	54	179	1.0	27.4	2.3	26.9	0.6	0.1	0.8	2.6	8.1	1.1	2.7	18	59	98.3	1.1
XII OTHER & UNSPECIFIED	3	9	2	3	8	17	25	0.3	100.0	0.3	100.0	1.0	0.7	0.1	0.2	0.5	0.4	0.4	6	8	72.0	4.0
a. Other specified	1	8	1	1	3	11	14	0.2	64.7	0.2	56.0	0.3	0.6	0.1	0.1	0.2	0.3	0.3	4	5	100.0	0.0
b. Other unspecified	2	1	1	2	5	6	11	0.1	35.3	0.1	44.0	0.6	0.1	0.1	0.1	0.3	0.1	0.2	2	4	36.4	9.1
TOTAL	586	2006	1352	1453	2302	5397	7699	100.0	100.0	100.0	100.0	187.0	162.1	90.7	98.6	149.6	122.6	128.7	1783	2531	94.1	0.5

† includes 294 non-malignant ‡ includes 9 non-malignant

Please consult the quality indicators for the constituent registries

USA, API (1998-2012)

	Males										M/F ratio		Females											
	Number of cases in age groups										0-14	0-19	Number of cases in age groups										0-14	0-19
	0	1-4	5-9	10-14	15-19	0-14	0-19	ASR per million	0-14	0-19			0	1-4	5-9	10-14	15-19	0-14	0-19	ASR per million	0-14	0-19		
I LEUKAEMIA	71	493	277	217	222	1058	1280	48.0	43.5	1.2	1.3	63	394	243	158	147	858	1005	40.2	35.5				
a. Lymphoid	28	390	227	130	117	775	892	35.3	30.7	1.2	1.3	31	329	184	99	53	643	696	30.3	25.1				
b. Acute myeloid	28	76	36	57	53	197	250	8.9	8.4	1.3	1.1	22	50	39	41	68	152	220	7.0	7.5				
c. CMD	5	2	5	19	36	31	67	1.3	2.0	1.1	1.7	3	5	8	12	12	28	40	1.2	1.3				
d. MDS & other	8	13	3	5	6	29	35	1.4	1.2	1.3	1.1	5	9	8	1	8	23	31	1.1	1.1				
e. Unspecified	2	12	6	6	10	26	36	1.2	1.2	2.2	2.0	2	1	4	5	6	12	18	0.5	0.6				
II LYMPHOMA & RELATED	13	94	117	158	249	382	631	16.4	19.8	1.8	1.5	21	37	61	91	199	210	409	9.3	13.1				
a. Hodgkin	0	11	30	57	127	98	225	4.0	6.8	2.0	1.5	0	4	8	36	102	48	150	2.0	4.6				
b. Non-Hodgkin except BL	4	34	50	72	94	160	254	6.8	8.0	1.6	1.4	3	15	37	46	82	101	183	4.4	5.9				
c. Burkitt (BL)	0	18	28	21	21	67	88	2.9	2.8	3.2	3.1	0	5	11	5	7	21	28	0.9	0.9				
d. Lymphoreticular	9	30	9	6	3	54	57	2.5	2.0	1.5	1.4	18	12	4	3	5	37	42	1.8	1.6				
e. Unspecified	0	1	0	2	4	3	7	0.1	0.2	1.0	1.2	0	1	1	1	3	3	6	0.1	0.2				
III CNS NEOPLASMS †	43	186	191	138	159	558	717	24.8	23.7	1.1	1.1	49	160	164	136	168	509	677	23.2	23.0				
a. Ependymoma	12	28	14	6	13	60	73	2.8	2.5	1.2	1.1	7	19	14	9	18	49	67	2.3	2.3				
b. Astrocytoma	11	67	58	62	57	198	255	8.7	8.4	1.0	1.0	16	65	58	54	50	193	243	8.8	8.3				
c. CNS embryonal	15	46	61	19	13	141	154	6.3	5.3	1.3	1.3	14	37	36	20	16	107	123	5.0	4.3				
d. Other gliomas	1	21	43	20	18	85	103	3.7	3.4	1.0	1.0	2	22	39	23	16	86	102	3.8	3.5				
e. Other specified	1	18	14	26	53	59	112	2.5	3.5	1.0	0.9	4	12	17	26	65	59	124	2.6	4.0				
f. Unspecified CNS	3	6	1	5	5	15	20	0.7	0.7	1.0	1.1	6	5	0	4	3	15	18	0.7	0.6				
IV NEUROBLASTOMA	59	95	17	4	4	175	179	8.4	6.7	1.2	1.2	42	83	19	0	8	144	152	7.2	5.8				
a. (Ganglioneuroblastoma	59	95	17	4	1	175	176	8.4	6.6	1.2	1.2	42	83	19	0	4	144	148	7.2	5.7				
b. Peripheral nervous	0	0	0	0	3	0	3	-	0.1	-	0.8	0	0	0	0	4	0	4	-	0.1				
V RETINOBLASTOMA	33	43	3	0	0	79	79	3.9	3.0	1.0	1.0	26	53	2	0	0	81	81	4.1	3.2				
VI RENAL TUMOURS	16	45	15	6	11	82	93	3.9	3.3	0.9	1.0	11	64	11	3	4	89	93	4.4	3.5				
a. Nephroblastoma	16	45	14	4	4	79	83	3.8	3.0	0.9	1.0	11	62	10	2	1	85	86	4.2	3.3				
b. Renal carcinoma	0	0	1	2	7	3	10	0.1	0.3	1.5	2.0	0	0	1	1	3	2	5	0.1	0.2				
c. Unspecified	0	0	0	0	0	0	0	-	-	0.0	0.0	0	2	0	0	0	2	2	0.1	0.1				
VII HEPATIC TUMOURS	25	58	10	10	19	103	122	4.9	4.3	1.9	1.9	17	21	9	6	11	53	64	2.6	2.3				
a. Hepatoblastoma	23	58	4	2	1	87	88	4.2	3.3	2.1	2.1	15	20	5	1	1	41	42	2.0	1.6				
b. Hepatic carcinoma	1	0	6	8	18	15	33	0.6	1.0	1.4	1.6	2	0	4	5	10	11	21	0.5	0.7				
c. Unspecified	1	0	0	0	0	1	1	0.0	0.0	1.0	1.0	0	1	0	0	0	1	1	0.1	0.0				
VIII BONE TUMOURS	2	9	32	67	102	110	212	4.5	6.4	1.1	1.3	1	6	32	64	66	103	169	4.3	5.3				
a. Osteosarcoma	0	1	22	45	61	68	129	2.7	3.9	0.9	1.1	0	2	21	51	43	74	117	3.1	3.7				
b. Chondrosarcoma	0	1	0	1	3	2	5	0.1	0.2	2.0	1.0	0	0	0	1	4	1	5	0.0	0.2				
c. Ewing & related	2	5	4	18	29	29	58	1.2	1.8	1.3	1.6	1	4	10	8	13	23	36	1.0	1.2				
d. Other specified	0	2	6	2	8	10	18	0.4	0.6	2.5	2.3	0	0	1	3	4	4	8	0.2	0.2				
e. Unspecified	0	0	0	1	1	1	2	0.0	0.1	1.0	0.7	0	0	0	1	2	1	3	0.0	0.1				
IX SOFT TISSUE SARCOMA	17	51	40	44	97	152	249	6.8	8.0	1.3	1.4	11	25	21	59	65	116	181	5.1	5.9				
a. Rhabdomyosarcoma	10	40	23	15	18	88	106	4.0	3.6	1.7	1.6	5	19	9	18	15	51	66	2.3	2.3				
b. Fibrosarcoma	3	5	3	3	8	14	22	0.6	0.7	0.8	0.9	4	1	3	9	7	17	24	0.7	0.8				
c. Kaposi sarcoma	0	0	0	0	1	0	1	-	0.0	-	-	0	0	0	0	0	0	0	-	-				
d. Other specified	2	5	9	20	52	36	88	1.5	2.7	1.0	1.3	1	5	7	23	33	36	69	1.5	2.2				
e. Unspecified	2	1	5	6	18	14	32	0.6	1.0	1.2	1.5	1	0	2	9	10	12	22	0.5	0.7				
X GERM CELL TUMOURS	33	43	19	69	183	164	347	7.2	10.8	1.0	1.3	24	20	35	78	112	157	269	6.9	8.7				
a. CNS germ cell ‡	2	4	17	57	53	80	133	3.2	4.0	1.8	2.5	3	6	11	24	9	44	53	1.9	1.7				
b. Other extragonadal	12	8	0	6	33	26	59	1.2	1.9	0.7	1.3	21	13	3	2	7	39	46	1.9	1.7				
c. Gonadal germ cell	18	31	2	6	95	57	152	2.7	4.8	0.8	1.1	0	1	21	48	67	70	137	2.9	4.3				
d. Gonadal carcinoma	0	0	0	0	1	0	1	-	0.0	0.0	0.0	0	0	0	3	25	3	28	0.1	0.8				
e. Unspecified gonadal	1	0	0	0	1	1	2	0.0	0.1	1.0	0.4	0	0	0	1	4	1	5	0.0	0.2				
XI CARCINOMA & MELANOMA	1	6	15	46	138	68	206	2.8	6.1	0.5	0.4	5	11	17	96	330	129	459	5.4	14.1				
a. Adrenocortical	0	2	0	0	1	2	3	0.1	0.1	0.4	0.6	1	1	1	2	0	5	5	0.2	0.2				
b. Thyroid	0	0	3	12	43	15	58	0.6	1.7	0.2	0.2	0	2	6	68	246	76	322	3.1	9.8				
c. Nasopharyngeal	0	0	3	10	18	13	31	0.5	0.9	-	2.6	0	0	0	0	12	0	12	-	0.4				
d. Melanoma	0	3	3	6	10	12	22	0.5	0.7	0.7	0.7	2	8	3	5	13	18	31	0.8	1.0				
e. Skin carcinoma	0	0	0	0	0	0	0	-	-	0.0	0.0	1	0	1	0	0	2	2	0.1	0.1				
f. Other & unspecified	1	1	6	18	66	26	92	1.1	2.7	0.9	1.1	1	0	6	21	59	28	87	1.2	2.7				
XII OTHER & UNSPECIFIED	1	4	1	0	3	6	9	0.3	0.3	0.5	0.6	2	5	1	3	5	11	16	0.5	0.6				
a. Other specified	0	4	0	0	1	4	5	0.2	0.2	0.6	0.6	1	4	1	1	2	7	9	0.3	0.3				
b. Other unspecified	1	0	1	0	2	2	4	0.1	0.1	0.5	0.6	1	1	0	2	3	4	7	0.2	0.2				
TOTAL	314	1127	737	759	1187	2937	4124	131.8	136.0	1.2	1.2	272	879	615	694	1115	2460	3575	113.2	121.1				

† includes 138 non-malignant in males and 156 non-malignant in females ‡ includes 5 non-malignant in males and 4 non-malignant in females

Please consult the quality indicators for the constituent registries

USA, API (1998-2012)

	Age group	Males	Females
Person-years	0	1 609 044	1 523 973
	1-4	6 270 082	6 101 931
	5-9	7 520 570	7 389 136
	10-14	7 507 148	7 221 783
	15-19	7 875 780	7 508 741
Total	0-14	22 906 844	22 236 823
	0-19	30 782 624	29 745 564
Average annual population	0-14	1 527 123	1 482 455
	0-19	2 052 175	1 983 038

Please consult the quality indicators for the constituent registries

USA, API (1998-2012)

Registry	Period	Cases	%	Person-years	%
Alabama	1998-2012	23	0.3	216 500	0.4
Alaska	1998-2012	43	0.6	202 610	0.3
Arizona	1998-2012	72	0.9	737 081	1.2
Arkansas	1998-2012	22	0.3	166 481	0.3
California	1998-2012	2708	35.2	19 245 093	31.8
Colorado	1998-2012	86	1.1	639 507	1.1
Connecticut	1998-2012	67	0.9	542 163	0.9
Delaware	1998-2012	10	0.1	106 178	0.2
District of Columbia	1998-2012	7	0.1	50 994	0.1
Florida	1998-2012	143	1.9	1 755 096	2.9
Georgia	1998-2012	163	2.1	1 208 881	2.0
Hawaii	1998-2012	563	7.3	3 964 128	6.5
Idaho	1998-2012	11	0.1	94 196	0.2
Illinois	1998-2012	304	3.9	2 238 140	3.7
Indiana	1998-2012	55	0.7	424 062	0.7
Iowa	1998-2012	27	0.4	238 695	0.4
Kansas	1998-2012	42	0.5	303 151	0.5
Kentucky	1998-2012	28	0.4	209 928	0.3
Louisiana	1998-2012	54	0.7	297 827	0.5
Maine	1998-2012	11	0.1	66 081	0.1
Maryland	1998-2012	99	1.3	1 197 250	2.0
Massachusetts	1998-2012	150	1.9	1 379 920	2.3
Michigan	1998-2012	93	1.2	1 103 510	1.8
Minnesota	1998-2012	191	2.5	1 131 848	1.9
Mississippi	2002-2012	7	0.1	87 481	0.1
Missouri	1998-2012	47	0.6	416 956	0.7
Montana	1998-2012	4	0.1	31 846	0.1
Nebraska	1998-2012	26	0.3	152 452	0.3
Nevada	1998-2012	76	1.0	682 717	1.1
New Hampshire	1998-2012	9	0.1	115 590	0.2
New Jersey	1998-2012	411	5.3	2 734 790	4.5
New Mexico	1998-2012	20	0.3	134 460	0.2
New York State	1998-2012	585	7.6	5 139 575	8.5
North Carolina	1998-2012	96	1.2	868 246	1.4
North Dakota	1998-2012	1	0.0	25 646	0.0
Ohio	1998-2012	85	1.1	797 249	1.3
Oklahoma	1998-2012	41	0.5	291 870	0.5
Oregon	1998-2012	93	1.2	670 569	1.1
Pennsylvania	1998-2012	158	2.1	1 363 986	2.3
Rhode Island	1998-2012	13	0.2	153 499	0.3
South Carolina	1998-2012	27	0.4	242 754	0.4
South Dakota	2001-2012	2	0.0	29 530	0.0
Tennessee	1999-2012	42	0.5	370 530	0.6
Texas	1998-2012	384	5.0	3 756 079	6.2
Utah	1998-2012	41	0.5	402 136	0.7
Vermont	1998-2012	3	0.0	36 415	0.1
Virginia	1998-2012	153	2.0	1 636 581	2.7
Washington State	1998-2012	285	3.7	2 074 625	3.4
West Virginia	1998-2012	7	0.1	48 721	0.1
Wisconsin	1998-2012	107	1.4	725 827	1.2
Wyoming	1998-2012	4	0.1	18 738	0.0
USA	1998-2012	7699	100.0	60 528 188	100.0

Please consult the quality indicators for the constituent registries

America, North

Florida, API
(1998-2012)

Georgia, API
(1998-2012)

Massachusetts, API
(1998-2012)

Minnesota, API
(1998-2012)

	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR	Cases	0-14 M/F	ASR	Cases	0-19 M/F	ASR
I LEUKAEMIA	33	1.5	26.8	37	1.6	22.8	41	1.1	45.5	47	1.0	39.9	32	0.8	32.5	43	1.0	31.8	61	1.3	74.2	71	1.3	65.5
a. Lymphoid	24	1.7	19.9	26	1.9	16.4	30	1.5	33.4	33	1.5	28.2	25	0.7	25.6	31	0.8	23.5	42	1.3	51.0	47	1.4	43.5
b. Acute myeloid	7	1.3	5.4	9	1.3	5.2	7	0.8	7.7	9	0.5	7.5	5	1.5	5.0	9	1.3	6.3	12	1.0	14.8	14	0.8	13.1
c. CMD	1	.	0.7	1	.	0.6	3	0.0	3.3	3	0.0	2.5	2	1.0	1.9	3	2.0	2.1	3	2.0	3.6	5	4.0	4.4
d. MDS & other	1	0.0	0.7	1	0.0	0.6	0	.	.	0	.	.	0	.	.	0	.	.	2	1.0	2.5	3	2.0	2.7
e. Unspecified	0	.	.	0	.	.	1	0.0	1.2	2	0.0	1.7	0	.	.	0	.	.	2	1.0	2.2	2	1.0	1.7
II LYMPHOMA & RELATED	7	2.5	5.1	17	1.8	8.9	11	1.8	11.9	16	1.3	13.1	12	1.0	11.8	23	1.6	15.8	15	1.5	17.9	22	1.2	19.4
a. Hodgkin	1	0.0	0.7	6	1.0	3.0	4	1.0	4.3	7	0.4	5.7	2	1.0	1.9	4	1.0	2.7	1	.	1.0	4	1.0	3.2
b. Non-Hodgkin except BL	3	2.0	2.1	6	2.0	3.1	6	2.0	6.4	8	3.0	6.5	6	0.5	5.8	12	1.0	8.1	8	1.0	9.3	12	1.0	10.4
c. Burkitt (BL)	2	.	1.4	3	2.0	1.6	1	.	1.2	1	.	0.9	3	2.0	3.0	6	5.0	4.1	3	2.0	3.6	3	2.0	2.8
d. Lymphoreticular	1	.	0.9	1	.	0.7	0	.	.	0	.	.	1	.	1.1	1	.	0.8	3	2.0	4.0	3	2.0	3.1
e. Unspecified	0	.	.	1	.	0.5	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
III CNS NEOPLASMS	† 19	1.1	14.8	21	1.1	12.5	28	1.0	30.5	34	0.8	28.3	32	1.1	32.5	38	0.9	28.8	20	0.8	24.0	26	0.9	23.4
a. Ependymoma	1	0.0	0.9	1	0.0	0.7	2	.	2.1	3	2.0	2.4	3	2.0	3.1	5	0.7	3.6	1	0.0	1.3	2	0.0	1.8
b. Astrocytoma	7	0.8	5.5	7	0.8	4.2	13	0.3	14.0	15	0.3	12.4	16	0.8	16.2	16	0.8	12.5	11	1.2	13.3	14	1.3	12.7
c. CNS embryonal	3	0.5	2.5	3	0.5	1.9	4	1.0	4.3	4	1.0	3.3	7	6.0	7.1	8	3.0	6.1	4	0.3	4.7	4	0.3	3.6
d. Other gliomas	3	2.0	2.5	3	2.0	1.9	6	5.0	6.5	6	5.0	5.0	2	0.0	2.0	3	0.0	2.2	0	.	.	1	.	0.8
e. Other specified	4	.	2.8	6	5.0	3.2	3	2.0	3.5	5	0.7	4.3	3	2.0	3.1	5	1.5	3.6	2	1.0	2.3	3	0.5	2.6
f. Unspecified CNS	1	0.0	0.7	1	0.0	0.5	0	.	.	1	.	0.8	1	0.0	1.1	1	0.0	0.8	2	1.0	2.4	2	1.0	1.8
IV NEUROBLASTOMA	14	1.8	11.8	14	1.8	9.1	7	0.8	8.2	7	0.8	6.4	5	4.0	5.3	5	4.0	4.1	7	2.5	9.0	7	2.5	7.0
a. (Ganglio)neuroblastoma	14	1.8	11.8	14	1.8	9.1	7	0.8	8.2	7	0.8	6.4	5	4.0	5.3	5	4.0	4.1	7	2.5	9.0	7	2.5	7.0
b. Peripheral nervous	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
V RETINOBLASTOMA	2	.	1.8	2	.	1.4	6	0.5	7.0	6	0.5	5.4	1	0.0	1.1	1	0.0	0.8	4	0.3	5.3	4	0.3	4.1
VI RENAL TUMOURS	5	0.3	4.3	5	0.3	3.3	5	0.3	5.9	5	0.3	4.5	3	2.0	3.2	3	2.0	2.5	5	.	6.6	5	.	5.1
a. Nephroblastoma	5	0.3	4.3	5	0.3	3.3	5	0.3	5.9	5	0.3	4.5	3	2.0	3.2	3	2.0	2.5	5	.	6.6	5	.	5.1
b. Renal carcinoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
VII HEPATIC TUMOURS	2	0.0	1.8	2	0.0	1.4	5	1.5	5.7	5	1.5	4.5	4	1.0	4.3	4	1.0	3.3	2	.	2.6	4	3.0	3.6
a. Hepatoblastoma	2	0.0	1.8	2	0.0	1.4	4	1.0	4.7	4	1.0	3.6	4	1.0	4.3	4	1.0	3.3	2	.	2.6	2	.	2.1
b. Hepatic carcinoma	0	.	.	0	.	.	1	.	1.1	1	.	0.8	0	.	.	0	.	.	0	.	.	2	1.0	1.6
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
VIII BONE TUMOURS	6	2.0	4.1	8	1.7	4.2	6	5.0	6.4	9	2.0	7.3	3	.	2.8	5	4.0	3.4	2	1.0	2.4	5	0.7	4.2
a. Osteosarcoma	5	1.5	3.4	6	2.0	3.2	2	.	2.1	4	3.0	3.2	0	.	.	1	0.0	0.6	1	0.0	1.3	4	0.3	3.4
b. Chondrosarcoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
c. Ewing & related	1	.	0.7	2	1.0	1.0	4	3.0	4.3	5	1.5	4.1	3	.	2.8	4	.	2.8	1	.	1.0	1	.	0.8
d. Other specified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
e. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
IX SOFT TISSUE SARCOMA	6	1.0	4.2	14	2.5	7.3	3	0.5	3.4	8	1.0	6.5	7	1.3	7.0	8	1.7	6.0	11	1.8	13.6	13	1.6	12.1
a. Rhabdomyosarcoma	1	.	0.7	5	4.0	2.6	2	1.0	2.3	2	1.0	1.8	2	1.0	2.0	2	1.0	1.6	4	.	5.3	4	.	4.1
b. Fibrosarcoma	2	0.0	1.5	4	1.0	2.1	0	.	.	1	0.0	0.8	0	.	.	0	.	.	2	1.0	2.4	2	1.0	1.8
c. Kaposi sarcoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
d. Other specified	2	1.0	1.3	4	3.0	2.0	1	0.0	1.0	3	2.0	2.3	3	0.5	3.1	4	1.0	3.0	4	0.3	4.6	6	0.5	5.1
e. Unspecified	1	.	0.7	1	.	0.5	0	.	.	2	1.0	1.5	2	.	1.9	2	.	1.5	1	.	1.3	1	.	1.0
X GERM CELL TUMOURS	7	2.5	5.4	11	1.8	6.2	8	1.7	8.7	13	1.6	10.6	6	1.0	6.3	10	1.0	7.3	11	1.8	13.0	16	2.2	14.0
a. CNS germ cell	4	3.0	2.9	4	3.0	2.2	1	.	1.0	2	.	1.6	2	1.0	2.0	2	1.0	1.6	5	4.0	5.9	7	2.5	6.2
‡																								
b. Other extragonadal	0	.	.	0	.	.	0	.	.	0	.	.	2	0.0	2.1	2	0.0	1.7	2	1.0	2.4	4	3.0	3.4
c. Gonadal germ cell	3	2.0	2.5	7	1.3	3.9	7	1.3	7.7	10	1.5	8.3	2	.	2.1	6	2.0	4.1	4	1.0	4.7	5	1.5	4.5
d. Gonadal carcinoma	0	.	.	0	.	.	0	.	.	1	0.0	0.8	0	.	.	0	.	.	0	.	.	0	.	.
e. Unspecified gonadal	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
XI CARCINOMA & MELANOMA	6	0.5	4.7	12	0.3	6.6	2	0.0	2.1	12	0.3	9.4	4	0.0	3.8	10	0.1	6.6	4	3.0	4.2	16	1.0	12.8
a. Adrenocortical	1	0.0	0.9	1	0.0	0.7	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
b. Thyroid	2	1.0	1.3	4	0.3	2.0	1	0.0	1.0	7	0.4	5.4	1	0.0	0.9	4	0.3	2.5	2	1.0	2.1	8	0.6	6.4
c. Nasopharyngeal	1	.	0.7	2	1.0	1.0	0	.	.	1	0.0	0.8	0	.	.	1	0.0	0.6	0	.	.	1	0.0	0.8
d. Melanoma	2	0.0	1.8	2	0.0	1.4	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
e. Skin carcinoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
f. Other & unspecified	0	.	.	3	0.5	1.5	1	0.0	1.1	4	0.3	3.1	3	0.0	2.8	5	0.0	3.4	2	.	2.1	7	2.5	5.6
XII OTHER & UNSPECIFIED	0	.	.	0	.	.	1	0.0	1.1	1	0.0	0.8	0	.	.	0	.	.	2	1.0	2.4	2	1.0	1.8
a. Other specified	0	.	.	0	.	.	1	0.0	1.1	1	0.0	0.8	0	.	.	0	.	.	1	.	1.3	1	.	1.0
b. Other unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	1	0.0	1.0	1	0.0	0.8
TOTAL	107	1.3	84.6	143	1.3	83.7	123	1.0																

America, North

Pennsylvania, API
(1998-2012)Virginia, API
(1998-2012)Washington State, API
(1998-2012)

	0-14			0-19			0-14			0-19			0-14			0-19		
	Cases	M/F	ASR	Cases	M/F	ASR	Cases	M/F	ASR	Cases	M/F	ASR	Cases	M/F	ASR	Cases	M/F	ASR
I LEUKAEMIA	41	1.4	42.0	50	1.2	38.1	36	0.7	29.4	46	0.7	28.6	54	1.6	36.6	67	1.5	33.7
a. Lymphoid	28	1.2	28.8	31	1.1	24.1	29	0.8	23.9	35	0.8	22.0	41	1.4	28.1	46	1.6	23.9
b. Acute myeloid	11	1.8	11.1	16	1.0	11.7	4	0.3	3.1	8	0.6	4.7	10	2.3	6.5	14	1.8	6.6
c. CMD	1	.	1.1	2	.	1.4	1	.	0.8	1	.	0.6	2	1.0	1.3	4	1.0	1.8
d. MDS & other	1	.	1.1	1	.	0.8	2	0.0	1.6	2	0.0	1.2	1	.	0.7	3	0.5	1.4
e. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
II LYMPHOMA & RELATED	4	0.3	3.8	9	0.5	6.0	13	1.6	10.2	22	2.1	13.1	19	1.4	12.1	39	1.4	17.6
a. Hodgkin	0	.	.	4	1.0	2.4	5	1.5	3.8	10	4.0	5.8	4	3.0	2.5	16	1.7	6.9
b. Non-Hodgkin except BL	3	0.0	2.8	4	0.0	2.8	5	4.0	4.0	9	2.0	5.4	10	0.7	6.4	17	0.9	7.8
c. Burkitt (BL)	1	.	1.0	1	.	0.8	2	1.0	1.5	2	1.0	1.2	1	.	0.6	1	.	0.5
d. Lymphoreticular	0	.	.	0	.	.	1	0.0	0.9	1	0.0	0.7	4	3.0	2.5	4	3.0	2.0
e. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	1	.	0.4
III CNS NEOPLASMS †	21	1.1	21.3	26	1.2	19.5	30	1.7	24.3	33	1.8	20.6	48	0.9	31.4	64	1.0	30.9
a. Ependymoma	2	.	2.2	2	.	1.7	3	.	2.6	3	.	2.0	3	0.5	2.1	5	0.7	2.5
b. Astrocytoma	9	0.5	9.2	11	0.6	8.3	11	2.7	8.8	13	2.3	8.0	17	0.5	11.2	24	0.6	11.6
c. CNS embryonal	5	1.5	4.9	6	2.0	4.4	7	0.8	5.7	7	0.8	4.4	9	3.5	6.2	9	3.5	4.8
d. Other gliomas	0	.	.	1	0.0	0.6	5	1.5	4.0	5	1.5	3.1	9	1.3	5.7	12	1.4	5.7
e. Other specified	4	1.0	4.0	5	1.5	3.7	2	0.0	1.6	3	0.5	1.8	9	0.5	5.6	13	0.9	6.0
f. Unspecified CNS	1	.	1.1	1	.	0.8	2	.	1.6	2	.	1.3	1	.	0.6	1	.	0.4
IV NEUROBLASTOMA	9	2.0	9.7	10	1.5	8.2	5	1.5	4.2	5	1.5	3.3	16	1.0	11.6	16	1.0	9.0
a. (Ganglio)neuroblastoma	9	2.0	9.7	10	1.5	8.2	5	1.5	4.2	5	1.5	3.3	16	1.0	11.6	16	1.0	9.0
b. Peripheral nervous	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
V RETINOBLASTOMA	8	1.7	8.7	8	1.7	6.7	3	0.5	2.6	3	0.5	2.0	5	0.7	3.7	5	0.7	2.9
VI RENAL TUMOURS	5	0.7	5.4	6	0.5	4.8	3	0.5	2.5	3	0.5	1.9	4	0.0	3.0	4	0.0	2.3
a. Nephroblastoma	5	0.7	5.4	5	0.7	4.2	3	0.5	2.5	3	0.5	1.9	4	0.0	3.0	4	0.0	2.3
b. Renal carcinoma	0	.	.	1	0.0	0.6	0	.	.	0	.	.	0	.	.	0	.	.
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
VII HEPATIC TUMOURS	1	.	1.1	1	.	0.8	2	1.0	1.6	2	1.0	1.3	9	1.3	6.4	11	1.2	5.8
a. Hepatoblastoma	1	.	1.1	1	.	0.8	1	.	0.9	1	.	0.7	8	1.0	5.8	8	1.0	4.5
b. Hepatic carcinoma	0	.	.	0	.	.	1	0.0	0.8	1	0.0	0.6	1	.	0.6	3	2.0	1.3
c. Unspecified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
VIII BONE TUMOURS	5	0.7	4.7	10	0.7	6.7	2	1.0	1.5	7	2.5	4.1	5	4.0	2.9	14	3.7	6.0
a. Osteosarcoma	5	0.7	4.7	7	0.8	4.9	1	0.0	0.8	5	1.5	2.9	5	4.0	2.9	9	3.5	3.9
b. Chondrosarcoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	1	0.0	0.4
c. Ewing & related	0	.	.	2	1.0	1.2	1	.	0.8	1	.	0.6	0	.	.	3	.	1.2
d. Other specified	0	.	.	1	0.0	0.6	0	.	.	0	.	.	0	.	.	1	.	0.4
e. Unspecified	0	.	.	0	.	.	0	.	.	1	.	0.6	0	.	.	0	.	.
IX SOFT TISSUE SARCOMA	7	2.5	7.3	7	2.5	5.6	7	0.4	5.5	13	0.9	7.8	15	0.7	9.6	22	0.8	10.3
a. Rhabdomyosarcoma	6	2.0	6.3	6	2.0	4.9	4	0.3	3.3	6	0.5	3.7	6	2.0	4.1	6	2.0	3.2
b. Fibrosarcoma	0	.	.	0	.	.	1	0.0	0.8	2	0.0	1.2	1	.	0.7	1	.	0.6
c. Kaposi sarcoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
d. Other specified	1	.	1.0	1	.	0.8	1	0.0	0.8	3	2.0	1.8	7	0.2	4.2	13	0.6	5.7
e. Unspecified	0	.	.	0	.	.	1	.	0.8	2	.	1.2	1	0.0	0.6	2	0.0	0.9
X GERM CELL TUMOURS	7	0.8	6.8	12	1.0	8.3	6	0.5	4.6	12	1.0	7.0	9	0.5	6.1	17	0.5	8.0
a. CNS germ cell	2	1.0	1.9	2	1.0	1.5	4	1.0	3.0	4	1.0	2.3	4	0.3	2.6	4	0.3	2.0
b. Other extragonadal	0	.	.	1	.	0.6	0	.	.	0	.	.	3	0.5	2.2	4	1.0	2.1
c. Gonadal germ cell	5	0.7	4.9	8	1.0	5.6	2	0.0	1.6	7	1.3	4.1	2	1.0	1.3	9	0.5	3.9
d. Gonadal carcinoma	0	.	.	0	.	.	0	.	.	1	0.0	0.6	0	.	.	0	.	.
e. Unspecified gonadal	0	.	.	1	0.0	0.6	0	.	.	0	.	.	0	.	.	0	.	.
XI CARCINOMA & MELANOMA	4	0.0	3.9	19	0.5	12.2	1	0.0	0.8	7	0.2	4.1	7	0.8	4.0	25	0.3	10.5
a. Adrenocortical	1	0.0	0.9	1	0.0	0.7	0	.	.	0	.	.	0	.	.	0	.	.
b. Thyroid	2	0.0	2.0	11	0.1	7.1	0	.	.	4	0.0	2.3	4	0.3	2.3	20	0.1	8.4
c. Nasopharyngeal	0	.	.	3	2.0	1.8	0	.	.	0	.	.	0	.	.	1	.	0.4
d. Melanoma	0	.	.	0	.	.	0	.	.	0	.	.	1	.	0.6	1	.	0.4
e. Skin carcinoma	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
f. Other & unspecified	1	0.0	0.9	4	3.0	2.6	1	0.0	0.8	3	0.5	1.7	2	1.0	1.2	3	2.0	1.3
XII OTHER & UNSPECIFIED	0	.	.	0	.	.	0	.	.	0	.	.	1	.	0.6	1	.	0.5
a. Other specified	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.	0	.	.
b. Other unspecified	0	.	.	0	.	.	0	.	.	0	.	.	1	.	0.6	1	.	0.5
TOTAL	112	1.2	114.7	158	1.0	117.0	108	1.0	87.1	153	1.1	93.7	192	1.1	128.2	285	1.0	137.6

† includes 6 non-malignant in Pennsylvania 6 non-malignant in Virginia 16 non-malignant in Washington State

Please consult the quality indicators for the constituent registries